Oslo (Norway), 22 May 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and RXi Pharmaceuticals (NASDAQ: RXII) a biotechnology company focused on developing novel RNAi therapeutics for significant un-met needs, today announced that they are extending their preclinical research collaboration initiated April 7, 2015.
This extension is supported by a new preclinical research collaboration agreement that reflect RXi’s recently completed acquisition of MirImmune and PCI Biotech’s focus in oncology. In brief, the preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
Please see attached press release for further details.
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
Per Walday, CEO, firstname.lastname@example.org, Mobile: +47 917 93 429.